Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection

  1. Noah Shopen
  2. Michal Dekel
  3. Michal Mizrahi
  4. Efrat Zandberg
  5. Daniel Talmud
  6. Neta Cohen

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.ejim.2022.03.001
  2. ScreenIT

    SciScore for 10.1101/2022.01.29.22270090: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: Ethics: Approval for this study was obtained from our institutional research ethics board.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    In addition, we collected laboratory and imaging test results, including white blood cell count and differential, neutrophil/lymphocytes ratio, C–reactive protein (CRP) level, SARS-CoV-2 IgG antibodies titers (in U/ml), and abnormal chest x-ray findings (see below).
    CRP
    suggested: None
    The system reports sCOVG assay results in index values and as nonreactive or reactive: nonreactive was defined by an index of <1.0, and those samples were considered negative for SARS-CoV-2 IgG antibodies, while reactive was defined by an index of ≥1.0, and those samples were considered positive for SARS-CoV-2 IgG antibodies.
    SARS-CoV-2 IgG
    suggested: None
    Software and Algorithms
    SentencesResources
    Statistical analysis: Data entry and analysis were performed with SPSS Statistics, version 26 (SPSS Inc, Chicago, IL).
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Our study has several limitations related to its retrospective nature. One is that some relevant data documented in the medical charts may have been incomplete, such as body mass index values and documented SARS-CoV-2 IgG levels. In addition, it was difficult to retrospectively discern how the co–occurrence of COVID-19 infection was affecting the clinical course of patients who were diagnosed with COVID-19 during their hospitalization for other reasons.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2022.01.29.22270090v1 on medRxiv